AUSTIN – XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test Natrunix as a treatment for Rheumatoid Arthritis. The randomized, double-blind, placebo-controlled, trial will examine the effectiveness of Natrunix to treat rheumatoid arthritis compared…Read More
XBiotech Inc FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients MarketScreener
